Live Breaking News & Updates on Cancer Core Quality

Stay updated with breaking news from Cancer core quality. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies

A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). ....

Outcomes Research , European Organisation For Research , Italian National Health Service , Italian National Health , European Organisation , Cancer Core Quality , Life Questionnaire , Rare Blood ,

Nirogacestat Linked With Improved Functional Status in Patients With Desmoid Tumors

Results presented at the National Community Oncology Dispensing Association International Spring Forum describe meaningful improvements in functioning among patients who received the oral gamma secretase inhibitor to treat progressing desmoid tumors. ....

United States , Nirogacestat Ogsiveo , International Spring Forum , European Organisation For Research , National Community Oncology Dispensing Association , Image Credit , Monkey Business , Physical Functioning , European Organisation , Cancer Core Quality , Life Questionnaire , Role Functioning , North America , Desmoid Tumors , Soft Tissue Sarcoma ,

FDA Approves Capivasertib Plus Fulvestrant in Advanced HR+/HER2– Breast Cancer With PIK3CA, AKT1, or PTEN Alterations

The FDA has approved capivasertib plus fulvestrant for the treatment of patients with HR-positive, HER2-negative, locally advanced or metastatic breast cancer harboring 1 or more PIK3CA, AKT1, or PTEN alteration, following progression on at least 1 endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. ....

European Organization For Research , Olivier Le Moal , European Organization , Cancer Core Quality , Life Questionnaire , Breast Cancer , Capivasertib With Fulvestrant ,